Emergent BioSolutions Reports Q2 2026 Results; Restructuring and CMO Exit

What Happened
Emergent BioSolutions Inc. announced its financial and operating results for the quarter ended June 30, 2026 (press release furnished as Exhibit 99.1) and will host an earnings call with presentation slides (Exhibit 99.2). On August 5, 2026 the company also announced a restructuring plan to reduce costs in response to business changes and disclosed related leadership changes.

Key Details

• The Restructuring Plan will reduce the workforce by approximately 93 employees and eliminate about 21 currently vacant positions; the company will close wet laboratories in Gaithersburg, Maryland.
• Expected annualized savings from the actions are approximately $40 million when fully implemented.
• Emergent estimates charges of approximately $10.0 million to $11.5 million related to the Restructuring Plan, primarily cash charges for severance, transition services and benefits, expected to be incurred mainly in the second half of 2026. Estimates are subject to local law, assumptions and may change.
• Executive changes: Simon Lowry, Chief Medical Officer & Head of R&D, will leave effective August 19, 2026. Stephanie Duatschek is promoted to Executive Vice President, Chief Growth Officer and will continue reporting to CEO Joseph Papa.

Why It Matters
These actions are intended to improve Emergent’s financial position by cutting costs and refocusing resources; the one-time charges ($10–11.5M) will likely affect near-term results while the $40M of annualized savings could improve future profitability if realized. The CMO’s departure and lab closures signal changes to R&D leadership and footprint that investors should watch for impacts on product development and pipeline timing. The company provided its results and supporting materials in the 8‑K and will discuss them on its earnings call.